Compare Medtronic PLC (MDT) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs BlackRock TCP Capital Corp — how do they compare? Medtronic PLC trades at $82.32 (market cap $106.61B), while BlackRock TCP Capital Corp trades at $3.24 (market cap $270.17M). The key difference: Medtronic PLC is far larger — about 394.6× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (26.09%). Which is the better fit depends on your goals.
| MDT | TCPC | |
|---|---|---|
Market Cap | $106.61B | $270.17M |
Sector | Health | Financials |
52-Week High | $105.35 | $7.64 |
52-Week Low | $73.75 | $3.14 |
Enterprise Value | $125.36B | — |
Dividend Yield | 3.46% | 26.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
TCPC trades at $3.21, down 3.02% today, with a bearish technical signal and negative revenue trends. The company reported a net loss of $88.93M in 2025, though it maintains a 112% net income margin due to accounting adjustments. Recent news includes a Zacks upgrade to Buy and an upcoming Q2 2026 earnings report on August 6, 2026.
Outlook remains cautious with mixed analyst sentiment (30.77% Buy) and ongoing legal scrutiny. The stock's low P/B of 0.49 suggests potential value, but persistent losses and negative cash flow pose significant risks. Dividend sustainability is a key concern amid financial pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
